IP Library Granted Patent US 8,722,400
Granted Patent B2
US 8,722,400 · App. 12/796,445 · Granted May 13, 2014

Artificial antigen presenting cells and uses therefor

Inventors: James L. Riley (Downingtown, PA); Carl H. June (Merion Station, PA); Robert H. Vonderheide (Merion Station, PA); Nicole Aqui (Philadelphia, PA); Megan M. Suhoski (Nuangola, PA)
Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,400
App. No.
12/796,445
Granted
May 13, 2014
Kind
B2
Abstract

The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.

Claims (4)

1. A method for specifically inducing proliferation of a T cell expressing a known co-stimulatory molecule, said method comprising contacting said T cell with an artificial presenting cell (aAPC) comprising at least one co-stimulatory ligand and CD64, wherein said CD64 is loaded with an anti-CD3 antibody, further wherein said CD64 is expressed from an exogenous expression vector, thereby specifically inducing proliferation of said T cell.

2. A method for specifically inducing proliferation of a T cell expressing a known co-stimulatory molecule, said method comprising contacting a population of T cells comprising at least one T cell expressing said known co-stimulatory molecule with an aAPC comprising at least one co-stimulatory ligand and CD64, wherein said CD64 is loaded with an anti-CD3 antibody, further wherein said CD64 is expressed from an exogenous expression vector, wherein binding of said known co-stimulatory molecule with said co-stimulatory ligand induces proliferation of said T cell.

3. The method of claim 1 , wherein said T cell is a CD8 T cell.

4. The method of claim 2 , wherein said T cell is a CD8 T cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2023
From: RILEY, JAMES L.; JUNE, CARL H.; VONDERHEIDE, ROBERT H.; AQUI, NICOLE; SUHOSKI, MEGAN M.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 064359/0443 →
CONFIRMATORY LICENSE Recorded May 28, 2015
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035771/0443 →
Continuity (3)
Continuation 11137807 · May 25, 2005
Provisional Application 60575712 · May 27, 2004
Related Publication 20110262467A1 · Oct 27, 2011